Centre Hospitalier De Perpignan — Clinical Trial Site

67 Registered trials

29 Currently recruiting

Organisation

Centre Hospitalier De Perpignan

Location

Perpignan Cedex, France

Identifier

ORG-100043107

Address

20 Avenue Du Languedoc, Cs 49954, 66046, France

Departments

1213: Recherche Clinique
Cardiology
gastro enterology
Gastroenterology
Hématologie
hématologie clinique
Hematology
Hematology Department
Hepato gastro enterology
Hépato-gastoentérologie
Hepato-gastroenterology
HepatoGastroEnterologie
Hepatogastroenterologue
hepatogastroenterology
Hepatogastroenterology and digestive cancer department
Infectious Diseases
Intensive Care Unit
Médecine Interne
Nephrology
Neurology
Oncology
oncology department
Perpignan
Pneumology
Pyrénées-orientales
Radiology
Réanimation
Rheumatology
Service d'Hematologie Clinique
Service d’Hématologie
Service des Maladies Infectieuses et Tropicales
Service Hématologie
SMIT
Unité de Recherche
Urgences pédiatriques

Clinical trials at this site (67)

Search interface

FILOCLL14 - STAIR : "Open-label, phase 2 study investigating the STop and restart Acalabrutinib In fRrail patients with previously untreated… Ended

2024-513936-80-00 elderly patients (> 70 years) with CLL or SLL 4 2021-11-12
IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre… Ended

2024-517215-67-00 Newly diagnosed Non-Frail transplant Ineligible Multipl 5 2021-06-11
KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA… Ended

2024-513252-15-00 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL 4 2021-01-28
Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Ended

2023-503384-41-00 Relapsed or refractory diffuse large B-cell lymphoma (D 5 2020-12-22
MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial Ended

2024-512269-14-00 GIant cell Arteritis 5 2020-01-27
A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su… Ended

2024-514088-25-00 Multiple Myeloma 5 2019-10-07
Trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failur… Ended

2024-512555-21-00 Metastatic colorectal cancer 5 2019-09-18
OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN A… Ended

2024-516048-24-00 CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR I 4 2019-06-19
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX) Ended

2024-510645-34-00 RAS and B-RAF wild-type metastatic colorectal cancer. R 4 2017-06-28
A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL… Ended

2024-515846-18-00 Newly diagnosed Diffuse Large B Cell Lymphoma 7 2016-09-19
Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted

2024-516687-28-00 Patients with GPA and inadequate response to standard o 5 2025-06-06
Evaluation of MEpolizumab-based regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic … Ended

2024-513653-75-00 Eosinophilic granulomatosis with polyangiitis (EGPA), f 5 2022-05-30
LAMSA2020: “A phase II randomized study to assess the efficacy on outcome of Venetoclax combined with Cytarabine versus Idarubicin combined… Ended

2022-502392-37-00 elderly patients (> = 60 years) with Acute Myeloid Leuk 4 2022-05-25
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Ri… Ended

2023-504036-17-00 Chronic Lymphocytic Leukemia (CLL) 5 2020-05-07
A RANDOMIZED TRIAL TESTING EARLY VERSUS LATE ONSET OF EPO ALFA TREATMENT IN LOWER RISK MDS WITH NON RBC TRANSFUSION DEPENDENT ANEMIA AND WI… Ended

2024-515356-21-00 Adult subject (18 years of age older) with low or inter 5 2018-04-17
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (… Ended

2024-516904-40-00 Previously Untreated Diffuse large B-cell lymphoma (DLB 5 2018-03-27
Interest of Intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease's lymphadenitis Ended

2024-512037-32-00 Bartonellosis 5 2017-05-31
Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended

2023-510361-97-00 Newly Diagnosed RARA-positive Adult Patients with Highe 5
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1)… Ended

2024-519258-35-00 stomach cancer 4